MX2018003893A - Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. - Google Patents

Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.

Info

Publication number
MX2018003893A
MX2018003893A MX2018003893A MX2018003893A MX2018003893A MX 2018003893 A MX2018003893 A MX 2018003893A MX 2018003893 A MX2018003893 A MX 2018003893A MX 2018003893 A MX2018003893 A MX 2018003893A MX 2018003893 A MX2018003893 A MX 2018003893A
Authority
MX
Mexico
Prior art keywords
cough
diaminopyrimidine
treatment
receptor modulators
methods
Prior art date
Application number
MX2018003893A
Other languages
English (en)
Inventor
Sereda GLAUB Kathleen
P Ford Anthony
Smith Steven
M Kitt Michael
Original Assignee
Afferent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afferent Pharmaceuticals Inc filed Critical Afferent Pharmaceuticals Inc
Publication of MX2018003893A publication Critical patent/MX2018003893A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Metodos de tratamiento de la tos, tos cronica y deseo de toser asociados con enfermedades respiratorias, con un antagonista del receptor P2X3 y/o P2X2/3, los métodos comprendiendo administrarle a un sujeto que lo necesite una cantidad eficaz de 5 un compuesto de la formula (I): ver fórmula (I), o una sal farmaceuticamente aceptable del mismo, en donde R1 y R2 son como se define en la presente.
MX2018003893A 2015-09-29 2016-09-23 Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. MX2018003893A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562234584P 2015-09-29 2015-09-29
US201662336381P 2016-05-13 2016-05-13
PCT/US2016/053223 WO2017058645A1 (en) 2015-09-29 2016-09-23 Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough

Publications (1)

Publication Number Publication Date
MX2018003893A true MX2018003893A (es) 2018-06-22

Family

ID=58424436

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003893A MX2018003893A (es) 2015-09-29 2016-09-23 Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.

Country Status (19)

Country Link
US (2) US11260056B2 (es)
EP (2) EP4215182A1 (es)
JP (1) JP6877441B2 (es)
KR (1) KR20180054843A (es)
AU (1) AU2016330466B2 (es)
CA (1) CA2998742C (es)
DK (1) DK3355889T3 (es)
ES (1) ES2942711T3 (es)
FI (2) FI3355889T3 (es)
HR (1) HRP20230445T1 (es)
HU (1) HUE061764T2 (es)
LT (1) LT3355889T (es)
MX (1) MX2018003893A (es)
NL (1) NL301260I2 (es)
PL (1) PL3355889T3 (es)
PT (1) PT3355889T (es)
RS (1) RS64155B1 (es)
SI (1) SI3355889T1 (es)
WO (1) WO2017058645A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017378785B2 (en) 2016-12-20 2021-07-29 Afferent Pharmaceuticals, Inc. Crystalline salts and polymorphs of a P2X3 antagonist
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
EA202092678A1 (ru) * 2018-05-15 2021-04-12 Байер Акциенгезельшафт 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон
BR112021005334A2 (pt) * 2018-10-05 2021-06-15 Shionogi & Co., Ltd. medicamento para tratamento de tosse crônica
EP3960179A4 (en) * 2019-04-30 2023-01-25 Beijing Tide Pharmaceutical Co., Ltd. METHOD OF TREATMENT OF COUGH USING A DIAMINOPYRIMIDINE COMPOUND
MA56022A (fr) 2019-05-31 2022-04-06 Chiesi Farm Spa Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
KR20220016074A (ko) 2019-05-31 2022-02-08 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 피리도피리미딘 유도체
CA3155142A1 (en) 2019-09-19 2021-03-25 Shionogi & Co., Ltd. Crystal of 1,3,5-triazine derivative or solvate thereof and method for producing same
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
CA3196335A1 (en) 2020-11-27 2022-06-02 Chiesi Farmaceutici S.P.A. Phthalazine derivatives as p2x3 inhibitors
MX2023005805A (es) 2020-11-27 2023-06-01 Chiesi Farm Spa Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3).
EP4251620A1 (en) 2020-11-27 2023-10-04 Chiesi Farmaceutici S.p.A. Amino quinazoline derivatives as p2x3 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343282B1 (en) 2004-03-05 2015-07-22 F. Hoffmann-La Roche AG Diaminopyrimidines as P2X3 and P2X2/3 antagonists
US20060029548A1 (en) 2004-07-22 2006-02-09 Amir Pelleg Methods of diagnosing, monitoring and treating pulmonary diseases
JP4850913B2 (ja) 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３及びｐ２ｘ２／３調節因子としてのジアミノピリジン
DK1924264T5 (en) 2005-09-01 2014-03-24 Hoffmann La Roche Diaminopyrimidines as P2X3- and P2X2 / 3 modulators
JP4850911B2 (ja) 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン
EP1926716B1 (en) 2005-09-01 2011-10-19 F. Hoffmann-La Roche AG Process for synthesis of aryloxy diaminopyrimidines
JP5128603B2 (ja) 2006-10-04 2013-01-23 エフ．ホフマン−ラ ロシュ アーゲー フェノキシジアミノピリミジン誘導体の合成方法
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
EP3865134A1 (en) * 2013-08-23 2021-08-18 Afferent Pharmaceuticals Inc. Methods of using diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases

Also Published As

Publication number Publication date
EP4215182A1 (en) 2023-07-26
EP3355889A4 (en) 2019-05-22
JP6877441B2 (ja) 2021-05-26
NL301260I2 (nl) 2024-03-25
US11260056B2 (en) 2022-03-01
AU2016330466A1 (en) 2018-03-29
HRP20230445T1 (hr) 2023-07-21
CA2998742A1 (en) 2017-04-06
LT3355889T (lt) 2023-05-10
EP3355889B1 (en) 2023-02-15
DK3355889T3 (da) 2023-05-15
FI3355889T3 (fi) 2023-05-15
WO2017058645A1 (en) 2017-04-06
SI3355889T1 (sl) 2023-07-31
FIC20240006I1 (fi) 2024-03-13
EP3355889A1 (en) 2018-08-08
CA2998742C (en) 2023-08-29
JP2018529776A (ja) 2018-10-11
RS64155B1 (sr) 2023-05-31
PL3355889T3 (pl) 2023-05-22
US20180280388A1 (en) 2018-10-04
ES2942711T3 (es) 2023-06-06
PT3355889T (pt) 2023-04-26
AU2016330466B2 (en) 2021-01-28
US20220143015A1 (en) 2022-05-12
HUE061764T2 (hu) 2023-08-28
KR20180054843A (ko) 2018-05-24

Similar Documents

Publication Publication Date Title
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
PH12016500357A1 (en) Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
MX2016000646A (es) Sulfonamidas como moduladores de canales de sodio.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
PH12018501903A1 (en) Methods of treating depression using orexin-2 receptor antagonists
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
PH12016502353A1 (en) Pharmaceutical composition
PH12016502352A1 (en) Pharmaceutical composition
MX2015012741A (es) Palbociclib deuterado.
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX2020002889A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo.
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
MX2019003710A (es) Compuestos y metodos de p2x3 y/o p2x2/3.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2018001684A (es) Metodo de curacion de heridas.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX368641B (es) Compuestos para el tratamiento de inflamación y dolor.
IN2014DE00822A (es)